Đang chuẩn bị liên kết để tải về tài liệu:
Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer

In the registration trial, cabozantinib exposure≥750 ng/mL correlated to improved tumor size reduction, response rate and progression free survival (PFS) in patients with metastatic renal cell cancer (mRCC). |